Roche (VTX:ROG) has been given a CHF 236 target price by analysts at Kepler Capital Markets in a research report issued to clients and investors on Tuesday, February 20th. The brokerage currently has a “neutral” rating on the healthcare company’s stock. Kepler Capital Markets’ price objective points to a potential upside of 3.40% from the company’s previous close.
Several other equities analysts have also recently weighed in on ROG. DZ Bank set a CHF 270 target price on shares of Roche and gave the company a “buy” rating in a research note on Friday, February 2nd. Sanford C. Bernstein set a CHF 262 price objective on shares of Roche and gave the stock a “buy” rating in a research report on Friday, December 1st. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Roche in a research report on Friday, February 2nd. Deutsche Bank set a CHF 264 price objective on shares of Roche and gave the stock a “neutral” rating in a research report on Tuesday, December 12th. Finally, UBS Group set a CHF 237 price objective on shares of Roche and gave the stock a “neutral” rating in a research report on Tuesday, February 20th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of CHF 255.05.
Shares of Roche (VTX:ROG) traded up CHF 0.05 during mid-day trading on Tuesday, reaching CHF 228.25. 2,210,000 shares of the company’s stock traded hands, compared to its average volume of 2,130,000. Roche has a 52-week low of CHF 214.30 and a 52-week high of CHF 273. The firm has a market cap of $197,010.00 and a P/E ratio of 22.73.
TRADEMARK VIOLATION WARNING: “Roche (ROG) PT Set at CHF 236 by Kepler Capital Markets” was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.thelincolnianonline.com/2018/03/14/kepler-capital-markets-analysts-give-roche-rog-a-chf-236-price-target.html.
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.